Drugs that bind to and activate the receptors for the hormones GLP-1 and GIP are effective in the treatment of obesity and diabetes. Surprisingly, active substances are currently being developed that ...

She suggested I start taking the GLP-1 Zepbound through weekly injections, along with incorporating a healthy diet and ...

With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from ...

There is a low incidence rate of suicide-related adverse events among adults with diabetes or obesity being treated with GLP-1 RAs.

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Merck MRK reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings of $2.22 per share rose 12% year over year, excluding foreign exchange ...

China These authors contributed equally to this work. Correspondence to: Dr. Xi Cao, Beijing Diabetes Institute, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University, No.

Accounting for mortality as competing risk, the Afib burden trended numerically in favor of the GLP-1 RA group (HR 0.85, 95% ...

SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.